{"gene":"SP7","run_date":"2026-06-10T07:46:38","timeline":{"discoveries":[{"year":2003,"finding":"BMP-2-induced Osterix (Osx) expression is mediated by Dlx5 but is independent of Runx2; antisense blocking of Dlx5 completely abrogated BMP-2-induced Osx expression, while Runx2 overexpression in myogenic C2C12 cells did not induce Osx, and Osx was still induced by BMP-2 in Runx2-null cells.","method":"Antisense knockdown of Dlx5, Runx2-null cells, BMP-2 treatment, RT-PCR","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal approaches (null cells, antisense knockdown, overexpression), replicated across multiple papers","pmids":["12963046"],"is_preprint":false},{"year":2006,"finding":"Runx2 directly transactivates the Osterix (Osx) promoter by binding to a Runx-responsive element in the proximal promoter region; mutation of this element abrogated Runx2-mediated transactivation.","method":"Promoter-reporter (luciferase) assays, deletion/mutation analysis, EMSA (Runx2 binding to Osx promoter DNA), 5' RACE","journal":"Gene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro promoter assays with mutagenesis plus direct DNA binding shown by EMSA, single lab but multiple orthogonal methods","pmids":["16574347"],"is_preprint":false},{"year":2007,"finding":"BMP-2 induces Osterix expression through Dlx5, which binds a homeodomain sequence in the proximal Osterix promoter; p38 MAPK phosphorylates Dlx5 at Ser-34 and Ser-217, increasing its transactivation potential and thereby driving Osterix expression.","method":"Promoter-reporter assays, ChIP, Dlx5 overexpression/knockdown, in vitro and in vivo kinase assays, site-directed mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with mutagenesis, ChIP, and functional overexpression/knockdown all in one study","pmids":["18056716"],"is_preprint":false},{"year":2008,"finding":"BMP2 regulates Osterix expression via two mechanisms: a Runx2-dependent pathway and a Runx2-independent pathway mediated by Smad1/Smad4 and Msx2; Smad6 (inhibitory Smad) suppresses BMP2-induced Osterix in Runx2-null cells, and knockdown of Msx2 inhibits BMP2-induced Osterix in Runx2-null mesenchymal cells.","method":"Overexpression of Smad1/Smad4/Smad6/Msx2, siRNA knockdown of Msx2, Runx2-null cells, RT-PCR, microarray","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal genetic tools (null cells, overexpression, siRNA), replicated findings across papers","pmids":["18703512"],"is_preprint":false},{"year":2010,"finding":"Osterix is phosphorylated by p38 MAPK at Ser-73 and Ser-77; phosphorylation at these sites enhances Osterix's ability to recruit the coactivators p300 and Brg1 (SWI/SNF) to the fibromodulin and bone sialoprotein promoters, increasing transcriptional activity. Osterix binds GC-rich (Sp1 consensus) sequences in these promoters.","method":"In vitro and in vivo p38 kinase assays, site-directed mutagenesis, ChIP, Co-IP (protein-protein interaction with p300 and Brg1), promoter-reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, ChIP, Co-IP, all in one study; single lab","pmids":["20682789"],"is_preprint":false},{"year":2014,"finding":"Osterix (Osx) and Runx2 physically interact and cooperatively induce osteogenic target genes (Col1a1, Fmod, Ibsp); this cooperation requires adjacent Sp1 and Runx2 DNA binding sites in target promoters and protein-protein interaction between Osx and Runx2. Phosphorylation of both proteins by p38 and ERK MAPKs at known sites is required for their physical interaction and cooperative transcriptional activity; mutation or inhibition of these phosphorylation sites disrupts complex formation.","method":"Co-IP, promoter-reporter assays, MAPK inhibition, mutagenesis of phosphorylation sites, ChIP","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — Co-IP, mutagenesis, functional reporter assays and ChIP in one study with multiple orthogonal methods","pmids":["25122769"],"is_preprint":false},{"year":2016,"finding":"Sp7/Osterix acts non-canonically: its zinc finger domain has reduced affinity for GC-box sequences (typical Sp family target) due to amino acid differences, and instead Sp7 engages osteoblast enhancers at AT-rich motifs through interaction with Dlx5. ChIP-seq identified a large set of predicted osteoblast enhancers; Dlx5 binding maps to the Sp7 zinc finger domain, supporting a model of Dlx-recruited Sp7 to AT-rich regulatory elements.","method":"ChIP-seq, transgenic mouse enhancer assays, cell culture reporter assays, domain mapping, amino acid sequence comparison","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — genome-scale ChIP-seq plus transgenic validation and biochemical domain mapping; multiple orthogonal methods","pmids":["27134141"],"is_preprint":false},{"year":2018,"finding":"SIRT7 deacylates Osterix (OSX) at lysine K368 in its C-terminal region, promoting OSX N-terminal transactivation activity. SIRT7 physically interacts with OSX. SIRT7-mediated deacylation of K368 also facilitates SIRT1-mediated depropionylation of OSX, further increasing transactivation activity. Germline and osteoblast-specific Sirt7 knockout mice show severe osteopenia with decreased bone formation.","method":"Co-IP, site-directed mutagenesis (K368), in vitro deacylation assay, Sirt7 knockout mice (germline and osteoblast-specific), bone histomorphometry","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical deacylation assay with mutagenesis, Co-IP, and two independent in vivo knockout models all in one study","pmids":["30026585"],"is_preprint":false},{"year":2021,"finding":"Sp7 drives osteocyte dendrite formation; deletion of Sp7 in osteoblasts/osteocytes causes defects in osteocyte dendrites. ChIP-seq and profiling of Sp7 target genes identified Osteocrin as a direct Sp7 target gene that promotes osteocyte dendrite formation and rescues dendrite defects in Sp7-deficient mice. Single-cell RNA-seq showed defects in osteocyte maturation without Sp7. Humans with SP7-R316C mutation show defective osteocyte morphology.","method":"Conditional Sp7 knockout mice, ChIP-seq, single-cell RNA-seq, rescue experiments with Osteocrin, histology, human genetic variant analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — conditional KO with defined cellular phenotype, ChIP-seq, rescue experiment, human genetic validation; multiple orthogonal methods","pmids":["34725346"],"is_preprint":false},{"year":2011,"finding":"Osterix (Osx) directly binds the Satb2 promoter at two GC-rich regions and transcriptionally activates Satb2 expression; Satb2 is downstream of Osx during bone formation. In Osx-null calvaria Satb2 is down-regulated; siRNA-mediated inhibition of Satb2 significantly inhibits Osx-induced osteoblast marker gene expression.","method":"Gel shift assay (EMSA), ChIP, promoter-reporter/deletion/point-mutation assays, siRNA knockdown, stable Osx-overexpressing cells (Tet-off system), qRT-PCR","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct DNA binding by EMSA and ChIP, mutagenesis, and functional epistasis experiments in one study","pmids":["21828043"],"is_preprint":false},{"year":2011,"finding":"Osterix (Osx) directly binds to and transcriptionally activates the VEGF promoter via two GC-rich regions; endogenous Osx associates with the native VEGF promoter in primary osteoblasts (ChIP). VEGF is down-regulated in Osx-null calvarial cells and in Osx conditional knockout mice tibiae.","method":"Gel shift assay, ChIP, promoter-reporter/deletion/point-mutation assays, siRNA knockdown, Tet-off overexpression, Osx-null and conditional KO mice, immunohistochemistry","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro DNA binding, ChIP, mutagenesis, and in vivo validation in KO mice","pmids":["22110141"],"is_preprint":false},{"year":2012,"finding":"MMP13 is a direct transcriptional target of Osterix (Osx) in osteoblasts; Osx binds a GC-rich region in the proximal 80 bp of the MMP13 promoter (EMSA and ChIP), and endogenous Osx is associated with the native MMP13 promoter in primary osteoblasts. MMP13 expression is dramatically reduced in Osx-null calvaria.","method":"Gel shift assay (EMSA), ChIP, promoter-reporter/deletion/point-mutation assays, siRNA knockdown, stable Osx-overexpressing cells, Osx-null mice","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro DNA binding (EMSA), ChIP, mutagenesis, and null mouse validation in one study","pmids":["23185634"],"is_preprint":false},{"year":2011,"finding":"Akt phosphorylates Osterix and increases its protein stability, osteogenic activity, and transcriptional activity. BMP-2 increases Osterix protein levels in an Akt-dependent manner.","method":"Kinase assay, overexpression of constitutively active Akt, luciferase reporter assays, protein stability assays, BMP-2 treatment with Akt inhibitors","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — kinase assay and functional readouts, but single lab and phosphorylation site not precisely mapped","pmids":["21777568"],"is_preprint":false},{"year":2011,"finding":"Erk1/2 regulates Osterix protein levels and transcriptional activity; constitutively active MEK increases Osterix mRNA, protein, and transcriptional activity and stabilizes Osterix protein, while MEK inhibitor (U0126) suppresses Osterix protein levels and transcriptional activity.","method":"Constitutively active MEK overexpression, MEK inhibitor U0126, luciferase reporter assays, protein stability assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional readouts with kinase pathway manipulation, single lab, single study","pmids":["22056560"],"is_preprint":false},{"year":2013,"finding":"Osterix is subject to ubiquitin-proteasome-mediated degradation; K58 and K230 are ubiquitination sites identified by Co-IP and protein stability assays. Mutation of K58 and K230 (K58R/K230R) promoted osteoblast differentiation markers and enhanced osteogenic differentiation in C2C12 cells.","method":"Co-IP (ubiquitination), proteasome inhibitor treatment, site-directed mutagenesis of lysine residues, luciferase reporter assays, osteogenic differentiation assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, mutagenesis, and functional differentiation assay; single lab but multiple methods","pmids":["23457570"],"is_preprint":false},{"year":2016,"finding":"Osterix is acetylated by CBP at K307 and K312; HDAC4 deacetylates Osterix. CBP-Osx interaction and co-localization were confirmed. Acetylation of Osx at K307/K312 enhances protein stability, DNA binding ability, and transcriptional activity, and is required for osteogenic differentiation of C2C12 cells.","method":"Co-IP, immunofluorescence colocalization, HDAC inhibitor treatment, site-directed mutagenesis (K307A/K312A), reporter assays, osteogenic differentiation assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, mutagenesis, and functional differentiation readout; single lab, multiple orthogonal methods","pmids":["27250035"],"is_preprint":false},{"year":2013,"finding":"CaMKII interacts with Osterix (Co-IP), increases Osterix protein levels, and enhances its transcriptional activity; CaMKII inhibitor KN-93 decreases Osterix protein levels, and siRNA knockdown of CaMKII decreases Osterix protein and transcriptional activity.","method":"Co-IP, CaMKII inhibitor (KN-93), siRNA knockdown, reporter assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP and functional reporter assays, single lab, no phosphorylation site mapping","pmids":["23402759"],"is_preprint":false},{"year":2017,"finding":"p53 physically interacts with Osterix (Osx/SP7) through a region adjacent to the OSX zinc fingers and the DNA-binding domain of p53; this interaction represses OSX transcriptional activity and inhibits OSX binding to GC-rich responsive Sp1 sites in osteogenic target gene promoters (IBSP, COL1A1). p53 also sequesters OSX from interacting with DLX5, blocking OSX co-factor activity at homeodomain-containing promoters.","method":"Co-IP (overexpressed and endogenous proteins), domain mapping, reporter assays, ChIP, conformational mutant analysis","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — Co-IP with domain mapping, ChIP, and functional reporter assays with mutagenesis in one study","pmids":["28777372"],"is_preprint":false},{"year":2014,"finding":"Runx2 (via its runt homology domain, RHD) physically interacts with Sp7/Osterix; co-expression of Runx2 and Sp7 synergistically activates the osteocalcin and FGF3 promoters (up to 130-fold), demonstrating cooperative transcriptional activation of cell-phenotype-restricted genes.","method":"Co-immunoprecipitation (endogenous proteins), domain mapping, promoter-reporter assays in epithelial and mesenchymal cells","journal":"Connective tissue research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — endogenous protein Co-IP, domain mapping, and functional reporter assays; single lab, multiple methods","pmids":["25158187"],"is_preprint":false},{"year":2014,"finding":"NO66 (a histone demethylase) interacts with Osterix and acts as a negative regulator of Osterix target genes. In Osx-null calvarial cells, the transcriptional repressors HP1 and NO66 occupancy at the Bsp gene is increased, while markers of active chromatin (H3K4me3, H3K36me3, H3ac) are reduced. Osx is required for active chromatin architecture at its target genes, and NO66 interacts with DNMT1A, HDAC1A, and HP1 to form repressor complexes; HP1 stimulates NO66 demethylase activity for H3K4me3 and H3K36me3.","method":"ChIP (multiple histone marks and transcriptional regulators), bisulfite sequencing (CpG methylation), Osx-null calvarial cells, Co-IP (NO66 with DNMT1A/HDAC1A/HP1)","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ChIP, Co-IP, null cells, methylation analysis; multiple orthogonal methods in one study","pmids":["24115157"],"is_preprint":false},{"year":2017,"finding":"Sp7 gene silencing in undifferentiated mesenchymal cells is mediated by DNMT1/3-, HDAC1/2/4-, Setdb1/Suv39h1-, and Ezh1/2-containing repressor complexes; Sp7 gene activation during osteoblast differentiation involves Tet1/Tet2-mediated DNA demethylation and SWI/SNF-mediated chromatin remodeling. Inhibition of DNA methylation triggers histone modification changes and chromatin remodeling leading to Sp7 gene expression; Tet1/Tet2 silencing prevents Sp7 expression and impairs recruitment of COMPASS, Jmjd2a/Jmjd3, and SWI/SNF complexes to the Sp7 promoter.","method":"ChIP, siRNA knockdown (DNMT, HDAC, Tet1/2, SWI/SNF components), bisulfite sequencing, pharmacologic inhibitors","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ChIP with multiple targets, knockdown of multiple epigenetic regulators, bisulfite sequencing; multiple orthogonal methods","pmids":["28784721"],"is_preprint":false},{"year":2022,"finding":"A de novo neomorphic missense variant in SP7 (p.S309W) alters the DNA-binding specificity of SP7 from AT-rich motifs (normal Sp7 target, distinct from other SP family members) to GC-consensus sequences (typical of other SP proteins), producing an aberrant gene expression profile including increased Col1a1 and endogenous Sp7 but decreased expression of genes involved in matrix mineralization. Corresponding knock-in mice recapitulate a complex skeletal phenotype distinct from Sp7-null mice.","method":"Structural/biochemical analysis of DNA binding specificity, knock-in mouse model, gene expression profiling, histomorphometry","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical binding specificity shift confirmed, knock-in mouse model with distinct phenotype, gene expression profiling; multiple orthogonal methods in one study","pmids":["35121733"],"is_preprint":false},{"year":2012,"finding":"miR-93 directly targets Sp7 by binding to the coding sequence (CDS) region of Sp7 mRNA, reducing Sp7 protein without affecting its mRNA level. Sp7 binds to the promoter of miR-93 (confirmed by EMSA, ChIP, and promoter-luciferase assay) and represses miR-93 transcription, forming a regulatory feedback loop that controls osteoblast mineralization.","method":"Luciferase reporter assay (CDS targeting), EMSA, ChIP, miRNA overexpression/knockdown, Western blot","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — EMSA, ChIP, reporter assay, and functional mineralization readout; multiple orthogonal methods in one study","pmids":["22467200"],"is_preprint":false},{"year":2013,"finding":"miR-322 promotes osteoblast differentiation partly by targeting Tob2, which normally binds and mediates degradation of Osx mRNA; miR-322 suppresses Tob2, thereby stabilizing Osx mRNA and increasing Osterix expression.","method":"miRNA gain/loss-of-function, luciferase reporter assay (Tob2 3'-UTR), qRT-PCR, osteogenic differentiation assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay confirming miR-322/Tob2 targeting plus functional rescue; single lab, multiple methods","pmids":["23564456"],"is_preprint":false},{"year":2010,"finding":"Sp7/Osterix directly upregulates mouse Col5a1 (pro-α1(V) collagen) gene expression in osteoblastic cells via an Sp1 binding site in the proximal promoter; overexpression increases Col5a1 promoter activity and endogenous mRNA, siRNA knockdown decreases both, and mutation of the Sp1 site abrogates the effect.","method":"Promoter-reporter assays, siRNA knockdown, overexpression, mutation analysis","journal":"Matrix biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — reporter assay with mutagenesis and siRNA; single lab, no direct DNA binding assay reported","pmids":["20888414"],"is_preprint":false},{"year":2010,"finding":"Sp7/Osterix upregulates Col5a3 (pro-α3(V) collagen) gene expression in osteoblastic cells via an Sp1 binding site in the core promoter; ChIP confirmed Sp7/Osterix interaction with the Col5a3 promoter in vivo.","method":"Promoter-reporter assays, siRNA knockdown, overexpression, ChIP","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay, siRNA, overexpression, and ChIP; single lab, multiple methods","pmids":["20206127"],"is_preprint":false},{"year":2014,"finding":"Sp7/Osterix induces Col1a2 (pro-α2(I) collagen) gene expression via a GC-rich sequence in the proximal promoter; overexpression and siRNA knockdown confirm this, and the GC-rich sequence is specifically required in osteoblastic cells.","method":"Promoter-reporter assays, mutagenesis, siRNA knockdown, overexpression, osteoblast differentiation model","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional promoter assays with mutagenesis; single lab, no direct DNA binding assay shown","pmids":["25172663"],"is_preprint":false},{"year":2016,"finding":"Osterix (Osx) and RUNX2 cooperatively activate SOST (sclerostin) expression in human osteoblasts by binding to specific SP-protein family and AML1 consensus sequences near the SOST transcription start site; ChIP confirmed OSX and RUNX2 binding to the SOST promoter.","method":"ChIP, promoter-reporter assays, overexpression of OSX and RUNX2","journal":"Calcified tissue international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assays; single lab, two methods","pmids":["27154028"],"is_preprint":false},{"year":2015,"finding":"Osterix (Osx) upregulates DKK1 expression in cementoblasts, thereby downregulating canonical Wnt/β-catenin signaling (reduced β-catenin nuclear translocation and TCF1 levels); Osx conditional knockout (cKO) mice show reduced DKK1 and increased β-catenin, consistent with in vitro data.","method":"Overexpression of Osx in cementoblast cell line, cKO mice (Osx loxP × 2.3Col1-Cre), Western blot, rescue experiments with DKK1, LiCl/Wnt3a treatments","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro mechanistic experiments corroborated by in vivo cKO data; single lab","pmids":["25678852"],"is_preprint":false},{"year":2006,"finding":"TNF-α inhibits Osterix (Osx) transcription via MEK1/ERK1 signaling (not JNK, p38, or NFκB); MEK/ERK inhibitors abrogate TNF inhibition of Osx mRNA and promoter activity. Two independent Osx promoters (upstream of Osx1 and Osx2 start sites) are both inhibited by TNF.","method":"Promoter-reporter assays, deletion/mutation analysis, pharmacological inhibitors, EMSA (nuclear protein binding), mRNA stability assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection of signaling pathway, promoter analysis, EMSA; single lab","pmids":["16410254"],"is_preprint":false},{"year":2006,"finding":"p38 MAPK positively regulates Osterix expression at both mRNA and protein levels; inhibition of p38 down-regulates Osx in osteoblasts, and this inhibitory effect is significantly relieved in osteoblasts overexpressing Osx. In p53-/- osteoblasts (with sustained Osx expression), p38 inhibition has minimal effect on differentiation.","method":"p38 inhibitor treatment, Osx overexpression, p53-/- osteoblasts, differentiation assays","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological epistasis; single lab, multiple approaches","pmids":["17185377"],"is_preprint":false},{"year":2007,"finding":"Runx3 directly binds to the Osterix promoter at a Runx-responsive element at -713 to -707 bp (site 3, AGTGGTT) and negatively regulates Osterix expression in dental pulp cells; mutation of site 3 abrogates Runx3-mediated down-regulation.","method":"Promoter-reporter assays with mutation analysis, EMSA, ChIP in dental pulp cells","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro DNA binding by EMSA, ChIP, and promoter mutagenesis; single lab, multiple orthogonal methods","pmids":["17352693"],"is_preprint":false},{"year":2009,"finding":"Parathyroid hormone (PTH) inhibits Osterix mRNA and protein expression in osteoblasts via stimulation of cAMP/PKA signaling (mimicked by forskolin/8-bromo-cAMP/caGsα), mapping to two promoter regions flanking the Osx1 start site (-304/-119 and -71/+91); inhibition did not require new protein synthesis and did not involve mRNA stability changes.","method":"PTH treatment, cAMP analogues, dominant-negative constructs, promoter-reporter assays with deletion mapping, mRNA stability assays","journal":"Journal of molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection of PKA pathway, promoter deletion mapping; single lab, multiple methods","pmids":["19505977"],"is_preprint":false},{"year":2013,"finding":"Osterix autoregulates its own promoter by binding to a tandem repeat sequence in the Osx2 promoter region that selectively binds OSX but not other Sp factors (Sp1, Sp3, Klf10). PTH inhibits this autoregulation partly through suppression of p38 MAPK; constitutively active MKK6 (p38 activator) blocks PTH inhibition of OSX.","method":"Promoter-reporter assays, point-mutation analysis of binding sites, p38 inhibitors, constitutively active MKK6 expression","journal":"Journal of molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter mutagenesis showing selectivity, pharmacological and genetic rescue; single lab","pmids":["23682129"],"is_preprint":false},{"year":2012,"finding":"SP7 overexpression in mature osteoblasts (using 2.3 kb Col1a1 promoter) causes osteopenia, reduces osteocyte process numbers, reduces expression of Col1a1, Spp1, Ibsp, and Bglap2, and inhibits bone mineralization at late stages. SP7 positively autoregulates its own promoter (confirmed by ChIP showing endogenous SP7 binding the proximal Sp7 promoter).","method":"Transgenic mice (2.3 kb Col1a1-Sp7), adenoviral shRNA/overexpression in primary osteoblasts, BrdU incorporation, ChIP, double-transgenic (Sp7/Runx2) analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — transgenic mouse with defined phenotype, ChIP, and loss-of-function in primary osteoblasts; multiple orthogonal approaches","pmids":["22396760"],"is_preprint":false},{"year":2017,"finding":"In odontoblasts, BMP-2 activates Dspp gene transcription via a Dlx3/Osx signaling pathway; Osx is a downstream target of Dlx3, and both Dlx3 and Osx activate the Dspp promoter. Protein-protein interaction between Dlx3 and Osx in odontoblasts was detected by Co-IP; two Dlx3 and one Osx binding sites on the Dspp promoter were confirmed by EMSA and ChIP.","method":"Co-IP, EMSA, ChIP, promoter-reporter/mutagenesis assays, luciferase assays, in vitro and in vivo BMP-2 treatment","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — Co-IP, EMSA, ChIP, mutagenesis all in one study; single lab","pmids":["28883412"],"is_preprint":false},{"year":2016,"finding":"TIEG1/KLF10 directly binds to and activates the Osterix promoter (confirmed by ChIP); TIEG1 is required for TGFβ- and BMP2-induced Osterix expression in osteoblasts. Loss of TIEG1 decreases Osterix mRNA, and restoration of TIEG1 in knockout osteoblasts rescues Osterix expression.","method":"ChIP, transfection reporter assays, siRNA knockdown, TIEG1 KO osteoblasts, domain mapping (zinc finger domain required)","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with reporter assay and genetic rescue; single lab, multiple methods","pmids":["26801561"],"is_preprint":false},{"year":2019,"finding":"Conditional deletion of Osterix (Osx) in chondrocytes (Col2-Cre-ERT2) impairs secondary ossification in the tibial epiphysis, reducing trabecular bone mass, trabecular number, and expression of MMP13, COL10, ALP, and BSP; Osx overexpression in ATDC5 chondrocytes increases Col10, Mmp13, Alp, and Bsp expression, supporting a role for chondrocyte Osx in regulating genes involved in hypertrophy and osteoblast transdifferentiation.","method":"Conditional knockout mice (Osx fl/fl; Col2-Cre-ERT2), tamoxifen induction, µCT, histology, IHC, overexpression in ATDC5 cells","journal":"Bone research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined skeletal phenotype, IHC, and gain-of-function in cell line; single lab, multiple approaches","pmids":["31646014"],"is_preprint":false},{"year":2019,"finding":"Sp7 directly regulates dlx2b and bglap expression in zebrafish through Sp7-binding sites on their promoters (confirmed by cell transfection reporter assays); loss of sp7 by CRISPR/Cas9 knockout reduces dlx2b and bglap expression and causes defects in bone mineralization and tooth development.","method":"CRISPR/Cas9 knockout in zebrafish, qRT-PCR, cell transfection promoter assays","journal":"Journal of biosciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined phenotype and promoter assays; single lab","pmids":["31894108"],"is_preprint":false},{"year":2017,"finding":"Melatonin inhibits ubiquitin-proteasome-mediated degradation of Osterix, thereby stabilizing its expression and increasing Osterix transcriptional activity on the osteogenic promoter. Melatonin-induced Osterix phosphorylation and transcriptional activity are blocked by PKA inhibitor H89 and PKC inhibitor Go6976.","method":"Proteasome inhibitor treatment, ubiquitination assays, PKA/PKC inhibitors, reporter assays, osteogenic differentiation assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological pathway dissection with functional readouts; single lab, mechanisms inferred through inhibitors rather than direct protein modification mapping","pmids":["28720849"],"is_preprint":false},{"year":2004,"finding":"The human SP7 gene encodes a 431 amino acid C2H2 zinc finger transcription factor of the SP family with three consecutive C2H2 zinc finger repeats; two alternatively spliced isoforms exist. SP7 maps to chromosome 12q13.13. SP7 mRNA is restricted to osteoblast-derived cell lines in vitro and is expressed specifically in osteoblasts in vivo (confirmed by in situ hybridization on human embryonic tissues).","method":"cDNA cloning, Northern blot, in situ hybridization, FISH (chromosomal mapping), sequence analysis","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct cloning, localization by ISH, and chromosomal mapping; single lab, multiple methods","pmids":["15474293"],"is_preprint":false},{"year":2024,"finding":"Osteoblast-specific deletion of Sp7 (using 2.3-kb Col1a1-EGFP-Cre) reveals that Sp7 inhibits proliferation of immature osteoblasts, induces osteoblast maturation and Col1a1 expression, and is required for osteocyte process formation; Sp7 overexpression directly induces Col1a1 expression. Loss of Sp7 in osteoblasts causes reduced osteocyte canaliculi, increased TUNEL-positive lacunae, increased osteoclasts, and cortical porosity.","method":"Conditional knockout mice (Sp7 fl/fl; 2.3kb-Col1a1-EGFP-Cre), hypomorphic Sp7 mice, micro-CT, histomorphometry, BrdU incorporation, RT-PCR, primary osteoblast cultures, Sp7 overexpression","journal":"Journal of orthopaedic translation","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent genetic mouse models with comprehensive skeletal analyses and gain-of-function validation; multiple orthogonal methods","pmids":["39027344"],"is_preprint":false},{"year":2021,"finding":"SIRT7 forms a complex with RBM6 that downregulates H3K18 acetylation at the OSX promoter, inhibiting OSX isoform 1 and 2 expression and osteogenic differentiation of MSCs. lncRNA PLXDC2-OT associates with the SIRT7/RBM6 complex, diminishing its binding and deacetylation activity at the OSX promoter and thereby promoting osteogenesis.","method":"Co-IP (SIRT7-RBM6 interaction), ChIP (H3K18Ac at OSX promoter), siRNA knockdown, lncRNA-protein interaction assay, osteogenic differentiation assays in vitro and in vivo","journal":"Stem cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ChIP, and functional rescue; single lab, multiple methods","pmids":["33684230"],"is_preprint":false}],"current_model":"SP7/Osterix is an osteoblast-specific C2H2 zinc finger transcription factor that acts downstream of BMP2/Runx2/Dlx5 signaling to drive osteoblast and osteocyte differentiation; it binds AT-rich osteoblast enhancers primarily as a co-factor with Dlx proteins (rather than canonical GC-boxes), physically interacts and cooperates with Runx2 to synergistically activate target genes (Col1a1, Ibsp, VEGF, MMP13, Satb2, SOST, osteocalcin, collagens V, DKK1, Osteocrin), and its transcriptional activity is modulated by multiple post-translational modifications—phosphorylation by p38 MAPK (Ser-73/77) and ERK/Akt, acetylation by CBP at K307/K312 (removed by HDAC4), deacylation at K368 by SIRT7—as well as by ubiquitin-proteasome-mediated degradation and epigenetic control of its own promoter via DNA methylation/demethylation (Tet1/2) and histone-modifying complexes including the repressor NO66."},"narrative":{"mechanistic_narrative":"SP7/Osterix is an osteoblast-specific C2H2 zinc finger transcription factor of the SP family whose expression is restricted to osteoblast lineage cells and required for osteoblast and osteocyte differentiation [PMID:15474293, PMID:39027344]. It is induced downstream of BMP-2 through both Runx2-dependent and Runx2-independent routes: Runx2 directly transactivates the Osx promoter [PMID:16574347], while a parallel Dlx5-mediated arm—itself amplified by p38 MAPK phosphorylation of Dlx5—drives Osx independently of Runx2 [PMID:12963046, PMID:18056716], with Smad1/Smad4/Msx2 providing an additional Runx2-independent input [PMID:18703512]. Unlike canonical SP proteins, the SP7 zinc finger has reduced GC-box affinity and instead is recruited to AT-rich osteoblast enhancers via interaction with Dlx5, defining a non-canonical co-factor mode of DNA engagement [PMID:27134141]; the disease relevance of this specificity is shown by a de novo neomorphic SP7 p.S309W variant that switches binding from AT-rich to GC-consensus sites and produces an aberrant osteogenic program and a distinct skeletal phenotype in knock-in mice [PMID:35121733]. SP7 also physically interacts with Runx2 and synergistically activates phenotype-restricted target genes, a cooperation requiring adjacent SP1/Runx2 sites and MAPK-dependent phosphorylation of both factors [PMID:25122769, PMID:25158187]. Through these mechanisms SP7 directly activates a broad osteogenic transcriptional program—including Satb2, VEGF, MMP13, SOST, fibromodulin, bone sialoprotein, type V and type I collagens, and Osteocrin—and in osteocytes drives dendrite/process formation, with Osteocrin acting as a direct target that rescues dendrite defects [PMID:21828043, PMID:22110141, PMID:23185634, PMID:34725346, PMID:39027344]. SP7 transcriptional output is tuned by extensive post-translational control: stimulatory phosphorylation by p38 MAPK (Ser-73/77, enhancing p300/Brg1 recruitment), ERK, and Akt [PMID:20682789, PMID:21777568, PMID:22056560], acetylation by CBP at K307/K312 reversed by HDAC4 [PMID:27250035], SIRT7-mediated deacylation at K368 [PMID:30026585], and ubiquitin-proteasome-mediated degradation at K58/K230 [PMID:23457570]; it is repressed by physical interaction with p53, which blocks both its DNA binding and its Dlx5 co-factor activity [PMID:28777372]. SP7 expression is itself governed by epigenetic switching of its promoter—silencing via DNMT/HDAC/Setdb1/Ezh repressor complexes and activation via Tet1/Tet2 demethylation and SWI/SNF remodeling—and by positive autoregulation through an SP7-selective promoter element [PMID:28784721, PMID:23682129, PMID:22396760].","teleology":[{"year":2003,"claim":"Established that BMP-2 induction of Osterix proceeds through Dlx5 independently of Runx2, revealing a branched upstream signaling logic for osteoblast commitment.","evidence":"Dlx5 antisense knockdown, Runx2-null cells, and Runx2 overexpression with BMP-2 treatment and RT-PCR","pmids":["12963046"],"confidence":"High","gaps":["Did not map the Dlx5 element on the Osx promoter","Did not exclude additional parallel inputs"]},{"year":2006,"claim":"Showed Runx2 directly binds and transactivates the Osx promoter, defining a Runx2-dependent arm of Osx induction alongside the Dlx5 route.","evidence":"Luciferase promoter-reporter assays, deletion/mutation analysis, EMSA, and 5' RACE","pmids":["16574347"],"confidence":"High","gaps":["In vitro promoter assays only","Relative contribution of Runx2 vs Dlx5 arms in vivo not quantified"]},{"year":2007,"claim":"Identified the Dlx5 homeodomain element on the Osx promoter and showed p38 phosphorylation of Dlx5 amplifies its transactivation, connecting BMP signaling to Osx induction mechanistically.","evidence":"Promoter-reporter assays, ChIP, kinase assays, and Dlx5 mutagenesis","pmids":["18056716"],"confidence":"High","gaps":["Focused on Dlx5 regulation rather than Osx protein function","Did not address Osx auto-feedback"]},{"year":2008,"claim":"Defined a Smad1/Smad4/Msx2-mediated Runx2-independent route for BMP2-driven Osx, expanding the upstream network beyond Dlx5.","evidence":"Smad/Msx2 overexpression, Msx2 siRNA in Runx2-null cells, RT-PCR, and microarray","pmids":["18703512"],"confidence":"High","gaps":["Direct Smad/Msx2 binding sites on Osx promoter not mapped","Crosstalk with Dlx5 arm unresolved"]},{"year":2010,"claim":"Demonstrated that p38 phosphorylation of Osterix at Ser-73/77 promotes coactivator recruitment, establishing PTM-controlled assembly of the transcriptional machinery at target promoters.","evidence":"Kinase assays, mutagenesis, ChIP, Co-IP with p300/Brg1, and reporter assays","pmids":["20682789"],"confidence":"High","gaps":["GC-box binding model later refined by non-canonical AT-rich mode","Single lab"]},{"year":2014,"claim":"Established that Osx and Runx2 physically interact and cooperatively activate osteogenic genes in a MAPK-phosphorylation-dependent manner, unifying the two upstream factors as a transcriptional complex.","evidence":"Co-IP, domain mapping, promoter-reporter assays, MAPK inhibition, and ChIP across two studies","pmids":["25122769","25158187"],"confidence":"High","gaps":["Stoichiometry and structure of the Osx-Runx2 complex unknown","Genome-wide co-occupancy not mapped"]},{"year":2016,"claim":"Resolved the central paradox of SP7's atypical DNA binding: its zinc finger has reduced GC-box affinity and engages AT-rich osteoblast enhancers via Dlx5, redefining SP7 as a Dlx-recruited co-factor.","evidence":"ChIP-seq, transgenic enhancer assays, domain mapping, and sequence comparison","pmids":["27134141"],"confidence":"High","gaps":["Structural basis of the Dlx5-zinc finger interface not solved","Direct vs indirect enhancer occupancy distinction incomplete"]},{"year":2018,"claim":"Identified SIRT7-mediated deacylation at K368 as a post-translational activator of Osx, linking a sirtuin to bone formation in vivo.","evidence":"Co-IP, in vitro deacylation assay, K368 mutagenesis, and germline/osteoblast-specific Sirt7 knockout mice","pmids":["30026585"],"confidence":"High","gaps":["Acyl group identity at K368 not fully defined","Interplay with other Osx PTMs not mapped"]},{"year":2021,"claim":"Established SP7's role in osteocyte dendrite formation and identified Osteocrin as a direct, rescuing target, extending SP7 function beyond osteoblast commitment into osteocyte maturation.","evidence":"Conditional knockout mice, ChIP-seq, single-cell RNA-seq, Osteocrin rescue, and human variant analysis","pmids":["34725346"],"confidence":"High","gaps":["Full set of dendrite-relevant SP7 targets not enumerated","Mechanism by which Osteocrin shapes dendrites unresolved"]},{"year":2022,"claim":"A neomorphic SP7 p.S309W variant that converts DNA-binding specificity from AT-rich to GC-consensus directly demonstrated that SP7's atypical specificity is functionally essential and disease-relevant.","evidence":"Biochemical DNA-binding analysis, knock-in mouse model, and expression profiling","pmids":["35121733"],"confidence":"High","gaps":["Structural mechanism of the specificity switch not solved","Spectrum of clinical SP7 variants not catalogued here"]},{"year":2024,"claim":"Comprehensive osteoblast-specific knockout defined SP7's dual role in suppressing immature osteoblast proliferation while driving maturation, Col1a1 expression, and osteocyte process formation.","evidence":"Two conditional/hypomorphic mouse models, micro-CT, histomorphometry, BrdU, and gain-of-function in primary osteoblasts","pmids":["39027344"],"confidence":"High","gaps":["Direct targets mediating proliferation arrest not identified","Mechanism of increased osteoclast/cortical porosity downstream unclear"]},{"year":null,"claim":"How the many post-translational modifications, p53 repression, and epigenetic promoter switches are integrated dynamically to set SP7 activity thresholds during osteoblast-to-osteocyte transition remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of the SP7-Dlx5-Runx2 enhancer complex","Hierarchy and crosstalk among PTMs not established","Quantitative model linking SP7 dosage to lineage stage lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[40,6,9,10,11,5,34]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[6,21,9,11,22]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[40,15,17]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[9,10,11,6,5]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,8,37,41]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[19,20,42]}],"complexes":[],"partners":["DLX5","RUNX2","SIRT7","TP53","CBP","NO66","DLX3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8TDD2","full_name":"Transcription factor Sp7","aliases":["Zinc finger protein osterix"],"length_aa":431,"mass_kda":45.0,"function":"Transcriptional activator essential for osteoblast differentiation (PubMed:23457570). Binds to SP1 and EKLF consensus sequences and to other G/C-rich sequences (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8TDD2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SP7","classification":"Not Classified","n_dependent_lines":10,"n_total_lines":1208,"dependency_fraction":0.008278145695364239},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SP7","total_profiled":1310},"omim":[{"mim_id":"619794","title":"VON WILLEBRAND FACTOR C DOMAIN-CONTAINING PROTEIN 2-LIKE; VWC2L","url":"https://www.omim.org/entry/619794"},{"mim_id":"613849","title":"OSTEOGENESIS IMPERFECTA, TYPE XII; OI12","url":"https://www.omim.org/entry/613849"},{"mim_id":"609951","title":"ZINC FINGER PROTEIN 384; ZNF384","url":"https://www.omim.org/entry/609951"},{"mim_id":"607278","title":"OSTEOFIBROUS DYSPLASIA, SUSCEPTIBILITY TO; OSFD","url":"https://www.omim.org/entry/607278"},{"mim_id":"606633","title":"TRANSCRIPTION FACTOR Sp7; SP7","url":"https://www.omim.org/entry/606633"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Not detected","tissue_distribution":"Not detected","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SP7"},"hgnc":{"alias_symbol":["osterix","OSX"],"prev_symbol":[]},"alphafold":{"accession":"Q8TDD2","domains":[{"cath_id":"3.30.160.60","chopping":"291-349","consensus_level":"medium","plddt":78.1,"start":291,"end":349},{"cath_id":"3.30.160","chopping":"351-381","consensus_level":"medium","plddt":76.7006,"start":351,"end":381}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TDD2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TDD2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TDD2-F1-predicted_aligned_error_v6.png","plddt_mean":51.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SP7","jax_strain_url":"https://www.jax.org/strain/search?query=SP7"},"sequence":{"accession":"Q8TDD2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8TDD2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8TDD2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TDD2"}},"corpus_meta":[{"pmid":"18703512","id":"PMC_18703512","title":"BMP2 regulates Osterix through Msx2 and Runx2 during osteoblast differentiation.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18703512","citation_count":427,"is_preprint":false},{"pmid":"12963046","id":"PMC_12963046","title":"BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12963046","citation_count":331,"is_preprint":false},{"pmid":"16574347","id":"PMC_16574347","title":"Runx2-mediated regulation of the zinc finger Osterix/Sp7 gene.","date":"2006","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/16574347","citation_count":260,"is_preprint":false},{"pmid":"16000303","id":"PMC_16000303","title":"BMP-2 and insulin-like growth factor-I mediate Osterix (Osx) expression in human mesenchymal stem cells via the MAPK and protein kinase D signaling pathways.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16000303","citation_count":259,"is_preprint":false},{"pmid":"19783797","id":"PMC_19783797","title":"Runx2, osx, and dspp in tooth development.","date":"2009","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/19783797","citation_count":223,"is_preprint":false},{"pmid":"23225263","id":"PMC_23225263","title":"Genetic and molecular control of osterix in skeletal formation.","date":"2013","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23225263","citation_count":223,"is_preprint":false},{"pmid":"24454809","id":"PMC_24454809","title":"Osx-Cre targets multiple cell types besides osteoblast lineage in postnatal mice.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24454809","citation_count":196,"is_preprint":false},{"pmid":"18056716","id":"PMC_18056716","title":"BMP-2 induces Osterix expression through up-regulation of Dlx5 and its phosphorylation by p38.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18056716","citation_count":185,"is_preprint":false},{"pmid":"20550694","id":"PMC_20550694","title":"Transcriptional regulation of bone formation by the osteoblast-specific transcription factor Osx.","date":"2010","source":"Journal of orthopaedic surgery and research","url":"https://pubmed.ncbi.nlm.nih.gov/20550694","citation_count":155,"is_preprint":false},{"pmid":"15786511","id":"PMC_15786511","title":"Osx transcriptional regulation is mediated by additional pathways to BMP2/Smad signaling.","date":"2005","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15786511","citation_count":130,"is_preprint":false},{"pmid":"16410254","id":"PMC_16410254","title":"Transcriptional regulation of the osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NF kappa B pathways.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16410254","citation_count":115,"is_preprint":false},{"pmid":"25122769","id":"PMC_25122769","title":"Mitogen-activated protein kinase (MAPK)-regulated interactions between Osterix and Runx2 are critical for the transcriptional osteogenic program.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25122769","citation_count":111,"is_preprint":false},{"pmid":"20682789","id":"PMC_20682789","title":"p38 regulates expression of osteoblast-specific genes by phosphorylation of osterix.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20682789","citation_count":109,"is_preprint":false},{"pmid":"27134141","id":"PMC_27134141","title":"Sp7/Osterix Is Restricted to Bone-Forming Vertebrates where It Acts as a Dlx Co-factor in Osteoblast Specification.","date":"2016","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/27134141","citation_count":103,"is_preprint":false},{"pmid":"17579353","id":"PMC_17579353","title":"Osterix/Sp7 regulates mesenchymal stem cell mediated endochondral ossification.","date":"2008","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17579353","citation_count":97,"is_preprint":false},{"pmid":"22467200","id":"PMC_22467200","title":"miR-93/Sp7 function loop mediates osteoblast mineralization.","date":"2012","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/22467200","citation_count":94,"is_preprint":false},{"pmid":"29741283","id":"PMC_29741283","title":"Long noncoding RNA MALAT1 promotes osterix expression to regulate osteogenic differentiation by targeting miRNA-143 in human bone marrow-derived mesenchymal stem cells.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29741283","citation_count":93,"is_preprint":false},{"pmid":"23430263","id":"PMC_23430263","title":"miR-145 and miR-143 regulate odontoblast differentiation through targeting Klf4 and Osx genes in a feedback loop.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23430263","citation_count":90,"is_preprint":false},{"pmid":"30026585","id":"PMC_30026585","title":"SIRT7 has a critical role in bone formation by regulating lysine acylation of SP7/Osterix.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30026585","citation_count":90,"is_preprint":false},{"pmid":"34725346","id":"PMC_34725346","title":"Control of osteocyte dendrite formation by Sp7 and its target gene osteocrin.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34725346","citation_count":89,"is_preprint":false},{"pmid":"26976234","id":"PMC_26976234","title":"Targeted disruption of sp7 and myostatin with CRISPR-Cas9 results in severe bone defects and more muscular cells in common carp.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26976234","citation_count":86,"is_preprint":false},{"pmid":"21898406","id":"PMC_21898406","title":"The transcription factor osterix (SP7) regulates BMP6-induced human osteoblast differentiation.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21898406","citation_count":80,"is_preprint":false},{"pmid":"17185377","id":"PMC_17185377","title":"p38 mitogen-activated protein kinase regulates osteoblast differentiation through osterix.","date":"2006","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17185377","citation_count":80,"is_preprint":false},{"pmid":"25670797","id":"PMC_25670797","title":"Scleraxis and osterix antagonistically regulate tensile force-responsive remodeling of the periodontal ligament and alveolar bone.","date":"2015","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25670797","citation_count":80,"is_preprint":false},{"pmid":"25550101","id":"PMC_25550101","title":"Osterix-Cre transgene causes craniofacial bone development defect.","date":"2014","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/25550101","citation_count":77,"is_preprint":false},{"pmid":"22396760","id":"PMC_22396760","title":"SP7 inhibits osteoblast differentiation at a late stage in mice.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22396760","citation_count":77,"is_preprint":false},{"pmid":"23564456","id":"PMC_23564456","title":"MicroRNA-322 (miR-322) and its target protein Tob2 modulate Osterix (Osx) mRNA stability.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23564456","citation_count":75,"is_preprint":false},{"pmid":"21828043","id":"PMC_21828043","title":"Osteoblast-specific transcription factor Osterix (Osx) is an upstream regulator of Satb2 during bone formation.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21828043","citation_count":74,"is_preprint":false},{"pmid":"27154028","id":"PMC_27154028","title":"Osterix and RUNX2 are Transcriptional Regulators of Sclerostin in Human Bone.","date":"2016","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/27154028","citation_count":73,"is_preprint":false},{"pmid":"25678852","id":"PMC_25678852","title":"Osterix controls cementoblast differentiation through downregulation of Wnt-signaling via enhancing DKK1 expression.","date":"2015","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25678852","citation_count":71,"is_preprint":false},{"pmid":"31827076","id":"PMC_31827076","title":"LncRNA ODIR1 inhibits osteogenic differentiation of hUC-MSCs through the FBXO25/H2BK120ub/H3K4me3/OSX axis.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31827076","citation_count":70,"is_preprint":false},{"pmid":"26992365","id":"PMC_26992365","title":"Osterix/Sp7 limits cranial bone initiation sites and is required for formation of sutures.","date":"2016","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/26992365","citation_count":68,"is_preprint":false},{"pmid":"28720849","id":"PMC_28720849","title":"Melatonin promotes osteoblast differentiation by regulating Osterix protein stability and expression.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28720849","citation_count":64,"is_preprint":false},{"pmid":"22110141","id":"PMC_22110141","title":"Transcriptional regulation of Vascular Endothelial Growth Factor (VEGF) by osteoblast-specific transcription factor Osterix (Osx) in osteoblasts.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22110141","citation_count":63,"is_preprint":false},{"pmid":"25139670","id":"PMC_25139670","title":"Skeletal defects in Osterix-Cre transgenic mice.","date":"2014","source":"Transgenic research","url":"https://pubmed.ncbi.nlm.nih.gov/25139670","citation_count":62,"is_preprint":false},{"pmid":"35538062","id":"PMC_35538062","title":"Klotho in Osx+-mesenchymal progenitors exerts pro-osteogenic and anti-inflammatory effects during mandibular alveolar bone formation and repair.","date":"2022","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35538062","citation_count":60,"is_preprint":false},{"pmid":"25568170","id":"PMC_25568170","title":"Osterix regulates tooth root formation in a site-specific manner.","date":"2015","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/25568170","citation_count":58,"is_preprint":false},{"pmid":"28777372","id":"PMC_28777372","title":"p53 inhibits SP7/Osterix activity in the transcriptional program of osteoblast differentiation.","date":"2017","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/28777372","citation_count":57,"is_preprint":false},{"pmid":"25870836","id":"PMC_25870836","title":"Different Methylation Patterns of RUNX2, OSX, DLX5 and BSP in Osteoblastic Differentiation of Mesenchymal Stem Cells.","date":"2015","source":"Cell journal","url":"https://pubmed.ncbi.nlm.nih.gov/25870836","citation_count":55,"is_preprint":false},{"pmid":"15474293","id":"PMC_15474293","title":"Molecular cloning, structure, expression, and chromosomal localization of the human Osterix (SP7) gene.","date":"2004","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/15474293","citation_count":54,"is_preprint":false},{"pmid":"21777568","id":"PMC_21777568","title":"Akt phosphorylates and regulates the osteogenic activity of Osterix.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21777568","citation_count":54,"is_preprint":false},{"pmid":"23300831","id":"PMC_23300831","title":"Synergistic inhibition of Wnt pathway by HIF-1α and osteoblast-specific transcription factor osterix (Osx) in osteoblasts.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23300831","citation_count":53,"is_preprint":false},{"pmid":"14604442","id":"PMC_14604442","title":"Expression of alternatively spliced isoforms of human Sp7 in osteoblast-like cells.","date":"2003","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/14604442","citation_count":53,"is_preprint":false},{"pmid":"20717928","id":"PMC_20717928","title":"Dexamethasone modulates osteogenesis and adipogenesis with regulation of osterix expression in rat calvaria-derived cells.","date":"2011","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20717928","citation_count":50,"is_preprint":false},{"pmid":"23185634","id":"PMC_23185634","title":"Matrix metalloproteinase 13 (MMP13) is a direct target of osteoblast-specific transcription factor osterix (Osx) in osteoblasts.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23185634","citation_count":50,"is_preprint":false},{"pmid":"25422448","id":"PMC_25422448","title":"Wnts produced by Osterix-expressing osteolineage cells regulate their proliferation and differentiation.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25422448","citation_count":47,"is_preprint":false},{"pmid":"26689368","id":"PMC_26689368","title":"Expression of osterix Is Regulated by FGF and Wnt/β-Catenin Signalling during Osteoblast Differentiation.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26689368","citation_count":46,"is_preprint":false},{"pmid":"16610234","id":"PMC_16610234","title":"Parathyroid hormone regulates osterix and Runx2 mRNA expression predominantly through protein kinase A signaling in osteoblast-like cells.","date":"2006","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16610234","citation_count":46,"is_preprint":false},{"pmid":"39337587","id":"PMC_39337587","title":"Regulation of Skeletal Development and Maintenance by Runx2 and Sp7.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39337587","citation_count":45,"is_preprint":false},{"pmid":"35669516","id":"PMC_35669516","title":"β-Ecdysterone Enhanced Bone Regeneration Through the BMP-2/SMAD/RUNX2/Osterix Signaling Pathway.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35669516","citation_count":44,"is_preprint":false},{"pmid":"31742679","id":"PMC_31742679","title":"Mg2+ in β-TCP/Mg-Zn composite enhances the differentiation of human bone marrow stromal cells into osteoblasts through MAPK-regulated Runx2/Osx.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31742679","citation_count":43,"is_preprint":false},{"pmid":"29382611","id":"PMC_29382611","title":"Novel variant in Sp7/Osx associated with recessive osteogenesis imperfecta with bone fragility and hearing impairment.","date":"2018","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/29382611","citation_count":42,"is_preprint":false},{"pmid":"27180803","id":"PMC_27180803","title":"TGF-β Signaling Regulates Cementum Formation through Osterix Expression.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27180803","citation_count":41,"is_preprint":false},{"pmid":"22056560","id":"PMC_22056560","title":"Osterix is regulated by Erk1/2 during osteoblast differentiation.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22056560","citation_count":41,"is_preprint":false},{"pmid":"23457570","id":"PMC_23457570","title":"Characterization of Osterix protein stability and physiological role in osteoblast differentiation.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23457570","citation_count":40,"is_preprint":false},{"pmid":"24115157","id":"PMC_24115157","title":"Osterix and NO66 histone demethylase control the chromatin of Osterix target genes during osteoblast differentiation.","date":"2014","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/24115157","citation_count":39,"is_preprint":false},{"pmid":"31709715","id":"PMC_31709715","title":"Deficiency of Macf1 in osterix expressing cells decreases bone formation by Bmp2/Smad/Runx2 pathway.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31709715","citation_count":38,"is_preprint":false},{"pmid":"19125191","id":"PMC_19125191","title":"Protein palmitoylation regulates osteoblast differentiation through BMP-induced osterix expression.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19125191","citation_count":37,"is_preprint":false},{"pmid":"27250035","id":"PMC_27250035","title":"Osterix acetylation at K307 and K312 enhances its transcriptional activity and is required for osteoblast differentiation.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27250035","citation_count":37,"is_preprint":false},{"pmid":"25865393","id":"PMC_25865393","title":"Ucma, a direct transcriptional target of Runx2 and Osterix, promotes osteoblast differentiation and nodule formation.","date":"2015","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/25865393","citation_count":36,"is_preprint":false},{"pmid":"31284378","id":"PMC_31284378","title":"CCN3 Facilitates Runx2 and Osterix Expression by Inhibiting miR-608 through PI3K/Akt Signaling in Osteoblasts.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31284378","citation_count":34,"is_preprint":false},{"pmid":"23402759","id":"PMC_23402759","title":"Calmodulin-dependent kinase II regulates osteoblast differentiation through regulation of Osterix.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23402759","citation_count":34,"is_preprint":false},{"pmid":"28784721","id":"PMC_28784721","title":"Tet-Mediated DNA Demethylation Is Required for SWI/SNF-Dependent Chromatin Remodeling and Histone-Modifying Activities That Trigger Expression of the Sp7 Osteoblast Master Gene during Mesenchymal Lineage Commitment.","date":"2017","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28784721","citation_count":33,"is_preprint":false},{"pmid":"27543160","id":"PMC_27543160","title":"Role of Osterix and MicroRNAs in Bone Formation and Tooth Development.","date":"2016","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/27543160","citation_count":32,"is_preprint":false},{"pmid":"35121733","id":"PMC_35121733","title":"A neomorphic variant in SP7 alters sequence specificity and causes a high-turnover bone disorder.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35121733","citation_count":31,"is_preprint":false},{"pmid":"23073571","id":"PMC_23073571","title":"Molecular mechanisms of osteoblast-specific transcription factor Osterix effect on bone formation.","date":"2012","source":"Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23073571","citation_count":30,"is_preprint":false},{"pmid":"35628456","id":"PMC_35628456","title":"Sp7 Action in the Skeleton: Its Mode of Action, Functions, and Relevance to Skeletal Diseases.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35628456","citation_count":29,"is_preprint":false},{"pmid":"28811640","id":"PMC_28811640","title":"A Reciprocal Interaction between β-Catenin and Osterix in Cementogenesis.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28811640","citation_count":29,"is_preprint":false},{"pmid":"31646014","id":"PMC_31646014","title":"Conditional disruption of the osterix gene in chondrocytes during early postnatal growth impairs secondary ossification in the mouse tibial epiphysis.","date":"2019","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/31646014","citation_count":29,"is_preprint":false},{"pmid":"20888414","id":"PMC_20888414","title":"Sp7/Osterix is involved in the up-regulation of the mouse pro-α1(V) collagen gene (Col5a1) in osteoblastic cells.","date":"2010","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/20888414","citation_count":29,"is_preprint":false},{"pmid":"22648388","id":"PMC_22648388","title":"Osterix is required for Sonic hedgehog-induced osteoblastic MC3T3-E1 cell differentiation.","date":"2012","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/22648388","citation_count":28,"is_preprint":false},{"pmid":"25600250","id":"PMC_25600250","title":"Identification of novel osteogenic compounds by an ex-vivo sp7:luciferase zebrafish scale assay.","date":"2015","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/25600250","citation_count":28,"is_preprint":false},{"pmid":"25158187","id":"PMC_25158187","title":"Sp7 and Runx2 molecular complex synergistically regulate expression of target genes.","date":"2014","source":"Connective tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/25158187","citation_count":27,"is_preprint":false},{"pmid":"28883412","id":"PMC_28883412","title":"BMP-2 induced Dspp transcription is mediated by Dlx3/Osx signaling pathway in odontoblasts.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28883412","citation_count":27,"is_preprint":false},{"pmid":"27689934","id":"PMC_27689934","title":"Epigenetic Signatures at the RUNX2-P1 and Sp7 Gene Promoters Control Osteogenic Lineage Commitment of Umbilical Cord-Derived Mesenchymal Stem Cells.","date":"2017","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27689934","citation_count":27,"is_preprint":false},{"pmid":"29288578","id":"PMC_29288578","title":"MiR-96 regulates bone metabolism by targeting osterix.","date":"2018","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29288578","citation_count":27,"is_preprint":false},{"pmid":"9608743","id":"PMC_9608743","title":"Identification and isolation of the indole-3-pyruvate decarboxylase gene from Azospirillum brasilense Sp7: sequencing and functional analysis of the gene locus.","date":"1998","source":"Current microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/9608743","citation_count":27,"is_preprint":false},{"pmid":"24407212","id":"PMC_24407212","title":"Osterix/Sp7 regulates biomineralization of otoliths and bone in medaka (Oryzias latipes).","date":"2014","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/24407212","citation_count":26,"is_preprint":false},{"pmid":"31894108","id":"PMC_31894108","title":"Sp7/osterix positively regulates dlx2b and bglap to affect tooth development and bone mineralization in zebrafish larvae.","date":"2019","source":"Journal of biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/31894108","citation_count":25,"is_preprint":false},{"pmid":"20206127","id":"PMC_20206127","title":"Sp7/Osterix up-regulates the mouse pro-alpha3(V) collagen gene (Col5a3) during the osteoblast differentiation.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20206127","citation_count":25,"is_preprint":false},{"pmid":"20014320","id":"PMC_20014320","title":"Polymethylmethacrylate particles impair osteoprogenitor viability and expression of osteogenic transcription factors Runx2, osterix, and Dlx5.","date":"2010","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/20014320","citation_count":25,"is_preprint":false},{"pmid":"22009963","id":"PMC_22009963","title":"Dynamic expression of Runx2, Osterix and AJ18 in the femoral head of steroid-induced osteonecrosis in rats.","date":"2010","source":"Orthopaedic surgery","url":"https://pubmed.ncbi.nlm.nih.gov/22009963","citation_count":25,"is_preprint":false},{"pmid":"26599722","id":"PMC_26599722","title":"Site-specific function and regulation of Osterix in tooth root formation.","date":"2016","source":"International endodontic journal","url":"https://pubmed.ncbi.nlm.nih.gov/26599722","citation_count":24,"is_preprint":false},{"pmid":"36659402","id":"PMC_36659402","title":"Zinc finger transcription factor Sp7/Osterix acts on bone formation and regulates col10a1a expression in zebrafish.","date":"2017","source":"Science bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/36659402","citation_count":23,"is_preprint":false},{"pmid":"36881265","id":"PMC_36881265","title":"SP7: from Bone Development to Skeletal Disease.","date":"2023","source":"Current osteoporosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/36881265","citation_count":22,"is_preprint":false},{"pmid":"19505977","id":"PMC_19505977","title":"Regulation of osterix (Osx, Sp7) and the Osx promoter by parathyroid hormone in osteoblasts.","date":"2009","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19505977","citation_count":22,"is_preprint":false},{"pmid":"21075078","id":"PMC_21075078","title":"The effects of Sp7/Osterix gene silencing in the chondroprogenitor cell line, ATDC5.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21075078","citation_count":22,"is_preprint":false},{"pmid":"32705283","id":"PMC_32705283","title":"miR‑27a‑3p negatively regulates osteogenic differentiation of MC3T3‑E1 preosteoblasts by targeting osterix.","date":"2020","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/32705283","citation_count":22,"is_preprint":false},{"pmid":"23682129","id":"PMC_23682129","title":"Regulation of the osterix (Osx, Sp7) promoter by osterix and its inhibition by parathyroid hormone.","date":"2013","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23682129","citation_count":21,"is_preprint":false},{"pmid":"25172663","id":"PMC_25172663","title":"Sp7/Osterix induces the mouse pro-α2(I) collagen gene (Col1a2) expression via the proximal promoter in osteoblastic cells.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25172663","citation_count":21,"is_preprint":false},{"pmid":"33684230","id":"PMC_33684230","title":"LncRNA, PLXDC2-OT promoted the osteogenesis potentials of MSCs by inhibiting the deacetylation function of RBM6/SIRT7 complex and OSX specific isoform.","date":"2021","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/33684230","citation_count":21,"is_preprint":false},{"pmid":"28657691","id":"PMC_28657691","title":"Pseudoshikonin I enhances osteoblast differentiation by stimulating Runx2 and Osterix.","date":"2017","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28657691","citation_count":21,"is_preprint":false},{"pmid":"30896834","id":"PMC_30896834","title":"miR‑124 regulates the osteogenic differentiation of bone marrow‑derived mesenchymal stem cells by targeting Sp7.","date":"2019","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30896834","citation_count":21,"is_preprint":false},{"pmid":"30450809","id":"PMC_30450809","title":"Osterix promotes the migration and angiogenesis of breast cancer by upregulation of S100A4 expression.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30450809","citation_count":20,"is_preprint":false},{"pmid":"39027344","id":"PMC_39027344","title":"Roles of Sp7 in osteoblasts for the proliferation, differentiation, and osteocyte process formation.","date":"2024","source":"Journal of orthopaedic translation","url":"https://pubmed.ncbi.nlm.nih.gov/39027344","citation_count":20,"is_preprint":false},{"pmid":"26801561","id":"PMC_26801561","title":"TIEG1 enhances Osterix expression and mediates its induction by TGFβ and BMP2 in osteoblasts.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26801561","citation_count":20,"is_preprint":false},{"pmid":"36210811","id":"PMC_36210811","title":"Identification of kaempferol as an OSX upregulator by network pharmacology-based analysis of qianggu Capsule for osteoporosis.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36210811","citation_count":20,"is_preprint":false},{"pmid":"17352693","id":"PMC_17352693","title":"Runx3 negatively regulates Osterix expression in dental pulp cells.","date":"2007","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/17352693","citation_count":20,"is_preprint":false},{"pmid":"35367406","id":"PMC_35367406","title":"Dominant osteogenesis imperfecta with low bone turnover caused by a heterozygous SP7 variant.","date":"2022","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/35367406","citation_count":20,"is_preprint":false},{"pmid":"25258338","id":"PMC_25258338","title":"The effects of osterix on the proliferation and odontoblastic differentiation of human dental papilla cells.","date":"2014","source":"Journal of endodontics","url":"https://pubmed.ncbi.nlm.nih.gov/25258338","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50405,"output_tokens":11088,"usd":0.158768,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21716,"output_tokens":3992,"usd":0.10419,"stage2_stop_reason":"end_turn"},"total_usd":0.262958,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"BMP-2-induced Osterix (Osx) expression is mediated by Dlx5 but is independent of Runx2; antisense blocking of Dlx5 completely abrogated BMP-2-induced Osx expression, while Runx2 overexpression in myogenic C2C12 cells did not induce Osx, and Osx was still induced by BMP-2 in Runx2-null cells.\",\n      \"method\": \"Antisense knockdown of Dlx5, Runx2-null cells, BMP-2 treatment, RT-PCR\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal approaches (null cells, antisense knockdown, overexpression), replicated across multiple papers\",\n      \"pmids\": [\"12963046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Runx2 directly transactivates the Osterix (Osx) promoter by binding to a Runx-responsive element in the proximal promoter region; mutation of this element abrogated Runx2-mediated transactivation.\",\n      \"method\": \"Promoter-reporter (luciferase) assays, deletion/mutation analysis, EMSA (Runx2 binding to Osx promoter DNA), 5' RACE\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro promoter assays with mutagenesis plus direct DNA binding shown by EMSA, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"16574347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"BMP-2 induces Osterix expression through Dlx5, which binds a homeodomain sequence in the proximal Osterix promoter; p38 MAPK phosphorylates Dlx5 at Ser-34 and Ser-217, increasing its transactivation potential and thereby driving Osterix expression.\",\n      \"method\": \"Promoter-reporter assays, ChIP, Dlx5 overexpression/knockdown, in vitro and in vivo kinase assays, site-directed mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with mutagenesis, ChIP, and functional overexpression/knockdown all in one study\",\n      \"pmids\": [\"18056716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BMP2 regulates Osterix expression via two mechanisms: a Runx2-dependent pathway and a Runx2-independent pathway mediated by Smad1/Smad4 and Msx2; Smad6 (inhibitory Smad) suppresses BMP2-induced Osterix in Runx2-null cells, and knockdown of Msx2 inhibits BMP2-induced Osterix in Runx2-null mesenchymal cells.\",\n      \"method\": \"Overexpression of Smad1/Smad4/Smad6/Msx2, siRNA knockdown of Msx2, Runx2-null cells, RT-PCR, microarray\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal genetic tools (null cells, overexpression, siRNA), replicated findings across papers\",\n      \"pmids\": [\"18703512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Osterix is phosphorylated by p38 MAPK at Ser-73 and Ser-77; phosphorylation at these sites enhances Osterix's ability to recruit the coactivators p300 and Brg1 (SWI/SNF) to the fibromodulin and bone sialoprotein promoters, increasing transcriptional activity. Osterix binds GC-rich (Sp1 consensus) sequences in these promoters.\",\n      \"method\": \"In vitro and in vivo p38 kinase assays, site-directed mutagenesis, ChIP, Co-IP (protein-protein interaction with p300 and Brg1), promoter-reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, ChIP, Co-IP, all in one study; single lab\",\n      \"pmids\": [\"20682789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Osterix (Osx) and Runx2 physically interact and cooperatively induce osteogenic target genes (Col1a1, Fmod, Ibsp); this cooperation requires adjacent Sp1 and Runx2 DNA binding sites in target promoters and protein-protein interaction between Osx and Runx2. Phosphorylation of both proteins by p38 and ERK MAPKs at known sites is required for their physical interaction and cooperative transcriptional activity; mutation or inhibition of these phosphorylation sites disrupts complex formation.\",\n      \"method\": \"Co-IP, promoter-reporter assays, MAPK inhibition, mutagenesis of phosphorylation sites, ChIP\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — Co-IP, mutagenesis, functional reporter assays and ChIP in one study with multiple orthogonal methods\",\n      \"pmids\": [\"25122769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Sp7/Osterix acts non-canonically: its zinc finger domain has reduced affinity for GC-box sequences (typical Sp family target) due to amino acid differences, and instead Sp7 engages osteoblast enhancers at AT-rich motifs through interaction with Dlx5. ChIP-seq identified a large set of predicted osteoblast enhancers; Dlx5 binding maps to the Sp7 zinc finger domain, supporting a model of Dlx-recruited Sp7 to AT-rich regulatory elements.\",\n      \"method\": \"ChIP-seq, transgenic mouse enhancer assays, cell culture reporter assays, domain mapping, amino acid sequence comparison\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — genome-scale ChIP-seq plus transgenic validation and biochemical domain mapping; multiple orthogonal methods\",\n      \"pmids\": [\"27134141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SIRT7 deacylates Osterix (OSX) at lysine K368 in its C-terminal region, promoting OSX N-terminal transactivation activity. SIRT7 physically interacts with OSX. SIRT7-mediated deacylation of K368 also facilitates SIRT1-mediated depropionylation of OSX, further increasing transactivation activity. Germline and osteoblast-specific Sirt7 knockout mice show severe osteopenia with decreased bone formation.\",\n      \"method\": \"Co-IP, site-directed mutagenesis (K368), in vitro deacylation assay, Sirt7 knockout mice (germline and osteoblast-specific), bone histomorphometry\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical deacylation assay with mutagenesis, Co-IP, and two independent in vivo knockout models all in one study\",\n      \"pmids\": [\"30026585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Sp7 drives osteocyte dendrite formation; deletion of Sp7 in osteoblasts/osteocytes causes defects in osteocyte dendrites. ChIP-seq and profiling of Sp7 target genes identified Osteocrin as a direct Sp7 target gene that promotes osteocyte dendrite formation and rescues dendrite defects in Sp7-deficient mice. Single-cell RNA-seq showed defects in osteocyte maturation without Sp7. Humans with SP7-R316C mutation show defective osteocyte morphology.\",\n      \"method\": \"Conditional Sp7 knockout mice, ChIP-seq, single-cell RNA-seq, rescue experiments with Osteocrin, histology, human genetic variant analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — conditional KO with defined cellular phenotype, ChIP-seq, rescue experiment, human genetic validation; multiple orthogonal methods\",\n      \"pmids\": [\"34725346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Osterix (Osx) directly binds the Satb2 promoter at two GC-rich regions and transcriptionally activates Satb2 expression; Satb2 is downstream of Osx during bone formation. In Osx-null calvaria Satb2 is down-regulated; siRNA-mediated inhibition of Satb2 significantly inhibits Osx-induced osteoblast marker gene expression.\",\n      \"method\": \"Gel shift assay (EMSA), ChIP, promoter-reporter/deletion/point-mutation assays, siRNA knockdown, stable Osx-overexpressing cells (Tet-off system), qRT-PCR\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct DNA binding by EMSA and ChIP, mutagenesis, and functional epistasis experiments in one study\",\n      \"pmids\": [\"21828043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Osterix (Osx) directly binds to and transcriptionally activates the VEGF promoter via two GC-rich regions; endogenous Osx associates with the native VEGF promoter in primary osteoblasts (ChIP). VEGF is down-regulated in Osx-null calvarial cells and in Osx conditional knockout mice tibiae.\",\n      \"method\": \"Gel shift assay, ChIP, promoter-reporter/deletion/point-mutation assays, siRNA knockdown, Tet-off overexpression, Osx-null and conditional KO mice, immunohistochemistry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro DNA binding, ChIP, mutagenesis, and in vivo validation in KO mice\",\n      \"pmids\": [\"22110141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MMP13 is a direct transcriptional target of Osterix (Osx) in osteoblasts; Osx binds a GC-rich region in the proximal 80 bp of the MMP13 promoter (EMSA and ChIP), and endogenous Osx is associated with the native MMP13 promoter in primary osteoblasts. MMP13 expression is dramatically reduced in Osx-null calvaria.\",\n      \"method\": \"Gel shift assay (EMSA), ChIP, promoter-reporter/deletion/point-mutation assays, siRNA knockdown, stable Osx-overexpressing cells, Osx-null mice\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro DNA binding (EMSA), ChIP, mutagenesis, and null mouse validation in one study\",\n      \"pmids\": [\"23185634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Akt phosphorylates Osterix and increases its protein stability, osteogenic activity, and transcriptional activity. BMP-2 increases Osterix protein levels in an Akt-dependent manner.\",\n      \"method\": \"Kinase assay, overexpression of constitutively active Akt, luciferase reporter assays, protein stability assays, BMP-2 treatment with Akt inhibitors\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — kinase assay and functional readouts, but single lab and phosphorylation site not precisely mapped\",\n      \"pmids\": [\"21777568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Erk1/2 regulates Osterix protein levels and transcriptional activity; constitutively active MEK increases Osterix mRNA, protein, and transcriptional activity and stabilizes Osterix protein, while MEK inhibitor (U0126) suppresses Osterix protein levels and transcriptional activity.\",\n      \"method\": \"Constitutively active MEK overexpression, MEK inhibitor U0126, luciferase reporter assays, protein stability assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional readouts with kinase pathway manipulation, single lab, single study\",\n      \"pmids\": [\"22056560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Osterix is subject to ubiquitin-proteasome-mediated degradation; K58 and K230 are ubiquitination sites identified by Co-IP and protein stability assays. Mutation of K58 and K230 (K58R/K230R) promoted osteoblast differentiation markers and enhanced osteogenic differentiation in C2C12 cells.\",\n      \"method\": \"Co-IP (ubiquitination), proteasome inhibitor treatment, site-directed mutagenesis of lysine residues, luciferase reporter assays, osteogenic differentiation assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, mutagenesis, and functional differentiation assay; single lab but multiple methods\",\n      \"pmids\": [\"23457570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Osterix is acetylated by CBP at K307 and K312; HDAC4 deacetylates Osterix. CBP-Osx interaction and co-localization were confirmed. Acetylation of Osx at K307/K312 enhances protein stability, DNA binding ability, and transcriptional activity, and is required for osteogenic differentiation of C2C12 cells.\",\n      \"method\": \"Co-IP, immunofluorescence colocalization, HDAC inhibitor treatment, site-directed mutagenesis (K307A/K312A), reporter assays, osteogenic differentiation assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, mutagenesis, and functional differentiation readout; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"27250035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CaMKII interacts with Osterix (Co-IP), increases Osterix protein levels, and enhances its transcriptional activity; CaMKII inhibitor KN-93 decreases Osterix protein levels, and siRNA knockdown of CaMKII decreases Osterix protein and transcriptional activity.\",\n      \"method\": \"Co-IP, CaMKII inhibitor (KN-93), siRNA knockdown, reporter assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP and functional reporter assays, single lab, no phosphorylation site mapping\",\n      \"pmids\": [\"23402759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"p53 physically interacts with Osterix (Osx/SP7) through a region adjacent to the OSX zinc fingers and the DNA-binding domain of p53; this interaction represses OSX transcriptional activity and inhibits OSX binding to GC-rich responsive Sp1 sites in osteogenic target gene promoters (IBSP, COL1A1). p53 also sequesters OSX from interacting with DLX5, blocking OSX co-factor activity at homeodomain-containing promoters.\",\n      \"method\": \"Co-IP (overexpressed and endogenous proteins), domain mapping, reporter assays, ChIP, conformational mutant analysis\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — Co-IP with domain mapping, ChIP, and functional reporter assays with mutagenesis in one study\",\n      \"pmids\": [\"28777372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Runx2 (via its runt homology domain, RHD) physically interacts with Sp7/Osterix; co-expression of Runx2 and Sp7 synergistically activates the osteocalcin and FGF3 promoters (up to 130-fold), demonstrating cooperative transcriptional activation of cell-phenotype-restricted genes.\",\n      \"method\": \"Co-immunoprecipitation (endogenous proteins), domain mapping, promoter-reporter assays in epithelial and mesenchymal cells\",\n      \"journal\": \"Connective tissue research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — endogenous protein Co-IP, domain mapping, and functional reporter assays; single lab, multiple methods\",\n      \"pmids\": [\"25158187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NO66 (a histone demethylase) interacts with Osterix and acts as a negative regulator of Osterix target genes. In Osx-null calvarial cells, the transcriptional repressors HP1 and NO66 occupancy at the Bsp gene is increased, while markers of active chromatin (H3K4me3, H3K36me3, H3ac) are reduced. Osx is required for active chromatin architecture at its target genes, and NO66 interacts with DNMT1A, HDAC1A, and HP1 to form repressor complexes; HP1 stimulates NO66 demethylase activity for H3K4me3 and H3K36me3.\",\n      \"method\": \"ChIP (multiple histone marks and transcriptional regulators), bisulfite sequencing (CpG methylation), Osx-null calvarial cells, Co-IP (NO66 with DNMT1A/HDAC1A/HP1)\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ChIP, Co-IP, null cells, methylation analysis; multiple orthogonal methods in one study\",\n      \"pmids\": [\"24115157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Sp7 gene silencing in undifferentiated mesenchymal cells is mediated by DNMT1/3-, HDAC1/2/4-, Setdb1/Suv39h1-, and Ezh1/2-containing repressor complexes; Sp7 gene activation during osteoblast differentiation involves Tet1/Tet2-mediated DNA demethylation and SWI/SNF-mediated chromatin remodeling. Inhibition of DNA methylation triggers histone modification changes and chromatin remodeling leading to Sp7 gene expression; Tet1/Tet2 silencing prevents Sp7 expression and impairs recruitment of COMPASS, Jmjd2a/Jmjd3, and SWI/SNF complexes to the Sp7 promoter.\",\n      \"method\": \"ChIP, siRNA knockdown (DNMT, HDAC, Tet1/2, SWI/SNF components), bisulfite sequencing, pharmacologic inhibitors\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ChIP with multiple targets, knockdown of multiple epigenetic regulators, bisulfite sequencing; multiple orthogonal methods\",\n      \"pmids\": [\"28784721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A de novo neomorphic missense variant in SP7 (p.S309W) alters the DNA-binding specificity of SP7 from AT-rich motifs (normal Sp7 target, distinct from other SP family members) to GC-consensus sequences (typical of other SP proteins), producing an aberrant gene expression profile including increased Col1a1 and endogenous Sp7 but decreased expression of genes involved in matrix mineralization. Corresponding knock-in mice recapitulate a complex skeletal phenotype distinct from Sp7-null mice.\",\n      \"method\": \"Structural/biochemical analysis of DNA binding specificity, knock-in mouse model, gene expression profiling, histomorphometry\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical binding specificity shift confirmed, knock-in mouse model with distinct phenotype, gene expression profiling; multiple orthogonal methods in one study\",\n      \"pmids\": [\"35121733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-93 directly targets Sp7 by binding to the coding sequence (CDS) region of Sp7 mRNA, reducing Sp7 protein without affecting its mRNA level. Sp7 binds to the promoter of miR-93 (confirmed by EMSA, ChIP, and promoter-luciferase assay) and represses miR-93 transcription, forming a regulatory feedback loop that controls osteoblast mineralization.\",\n      \"method\": \"Luciferase reporter assay (CDS targeting), EMSA, ChIP, miRNA overexpression/knockdown, Western blot\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — EMSA, ChIP, reporter assay, and functional mineralization readout; multiple orthogonal methods in one study\",\n      \"pmids\": [\"22467200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"miR-322 promotes osteoblast differentiation partly by targeting Tob2, which normally binds and mediates degradation of Osx mRNA; miR-322 suppresses Tob2, thereby stabilizing Osx mRNA and increasing Osterix expression.\",\n      \"method\": \"miRNA gain/loss-of-function, luciferase reporter assay (Tob2 3'-UTR), qRT-PCR, osteogenic differentiation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay confirming miR-322/Tob2 targeting plus functional rescue; single lab, multiple methods\",\n      \"pmids\": [\"23564456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Sp7/Osterix directly upregulates mouse Col5a1 (pro-α1(V) collagen) gene expression in osteoblastic cells via an Sp1 binding site in the proximal promoter; overexpression increases Col5a1 promoter activity and endogenous mRNA, siRNA knockdown decreases both, and mutation of the Sp1 site abrogates the effect.\",\n      \"method\": \"Promoter-reporter assays, siRNA knockdown, overexpression, mutation analysis\",\n      \"journal\": \"Matrix biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — reporter assay with mutagenesis and siRNA; single lab, no direct DNA binding assay reported\",\n      \"pmids\": [\"20888414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Sp7/Osterix upregulates Col5a3 (pro-α3(V) collagen) gene expression in osteoblastic cells via an Sp1 binding site in the core promoter; ChIP confirmed Sp7/Osterix interaction with the Col5a3 promoter in vivo.\",\n      \"method\": \"Promoter-reporter assays, siRNA knockdown, overexpression, ChIP\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay, siRNA, overexpression, and ChIP; single lab, multiple methods\",\n      \"pmids\": [\"20206127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Sp7/Osterix induces Col1a2 (pro-α2(I) collagen) gene expression via a GC-rich sequence in the proximal promoter; overexpression and siRNA knockdown confirm this, and the GC-rich sequence is specifically required in osteoblastic cells.\",\n      \"method\": \"Promoter-reporter assays, mutagenesis, siRNA knockdown, overexpression, osteoblast differentiation model\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional promoter assays with mutagenesis; single lab, no direct DNA binding assay shown\",\n      \"pmids\": [\"25172663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Osterix (Osx) and RUNX2 cooperatively activate SOST (sclerostin) expression in human osteoblasts by binding to specific SP-protein family and AML1 consensus sequences near the SOST transcription start site; ChIP confirmed OSX and RUNX2 binding to the SOST promoter.\",\n      \"method\": \"ChIP, promoter-reporter assays, overexpression of OSX and RUNX2\",\n      \"journal\": \"Calcified tissue international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assays; single lab, two methods\",\n      \"pmids\": [\"27154028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Osterix (Osx) upregulates DKK1 expression in cementoblasts, thereby downregulating canonical Wnt/β-catenin signaling (reduced β-catenin nuclear translocation and TCF1 levels); Osx conditional knockout (cKO) mice show reduced DKK1 and increased β-catenin, consistent with in vitro data.\",\n      \"method\": \"Overexpression of Osx in cementoblast cell line, cKO mice (Osx loxP × 2.3Col1-Cre), Western blot, rescue experiments with DKK1, LiCl/Wnt3a treatments\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro mechanistic experiments corroborated by in vivo cKO data; single lab\",\n      \"pmids\": [\"25678852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TNF-α inhibits Osterix (Osx) transcription via MEK1/ERK1 signaling (not JNK, p38, or NFκB); MEK/ERK inhibitors abrogate TNF inhibition of Osx mRNA and promoter activity. Two independent Osx promoters (upstream of Osx1 and Osx2 start sites) are both inhibited by TNF.\",\n      \"method\": \"Promoter-reporter assays, deletion/mutation analysis, pharmacological inhibitors, EMSA (nuclear protein binding), mRNA stability assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection of signaling pathway, promoter analysis, EMSA; single lab\",\n      \"pmids\": [\"16410254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"p38 MAPK positively regulates Osterix expression at both mRNA and protein levels; inhibition of p38 down-regulates Osx in osteoblasts, and this inhibitory effect is significantly relieved in osteoblasts overexpressing Osx. In p53-/- osteoblasts (with sustained Osx expression), p38 inhibition has minimal effect on differentiation.\",\n      \"method\": \"p38 inhibitor treatment, Osx overexpression, p53-/- osteoblasts, differentiation assays\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological epistasis; single lab, multiple approaches\",\n      \"pmids\": [\"17185377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Runx3 directly binds to the Osterix promoter at a Runx-responsive element at -713 to -707 bp (site 3, AGTGGTT) and negatively regulates Osterix expression in dental pulp cells; mutation of site 3 abrogates Runx3-mediated down-regulation.\",\n      \"method\": \"Promoter-reporter assays with mutation analysis, EMSA, ChIP in dental pulp cells\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro DNA binding by EMSA, ChIP, and promoter mutagenesis; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"17352693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Parathyroid hormone (PTH) inhibits Osterix mRNA and protein expression in osteoblasts via stimulation of cAMP/PKA signaling (mimicked by forskolin/8-bromo-cAMP/caGsα), mapping to two promoter regions flanking the Osx1 start site (-304/-119 and -71/+91); inhibition did not require new protein synthesis and did not involve mRNA stability changes.\",\n      \"method\": \"PTH treatment, cAMP analogues, dominant-negative constructs, promoter-reporter assays with deletion mapping, mRNA stability assays\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection of PKA pathway, promoter deletion mapping; single lab, multiple methods\",\n      \"pmids\": [\"19505977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Osterix autoregulates its own promoter by binding to a tandem repeat sequence in the Osx2 promoter region that selectively binds OSX but not other Sp factors (Sp1, Sp3, Klf10). PTH inhibits this autoregulation partly through suppression of p38 MAPK; constitutively active MKK6 (p38 activator) blocks PTH inhibition of OSX.\",\n      \"method\": \"Promoter-reporter assays, point-mutation analysis of binding sites, p38 inhibitors, constitutively active MKK6 expression\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter mutagenesis showing selectivity, pharmacological and genetic rescue; single lab\",\n      \"pmids\": [\"23682129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SP7 overexpression in mature osteoblasts (using 2.3 kb Col1a1 promoter) causes osteopenia, reduces osteocyte process numbers, reduces expression of Col1a1, Spp1, Ibsp, and Bglap2, and inhibits bone mineralization at late stages. SP7 positively autoregulates its own promoter (confirmed by ChIP showing endogenous SP7 binding the proximal Sp7 promoter).\",\n      \"method\": \"Transgenic mice (2.3 kb Col1a1-Sp7), adenoviral shRNA/overexpression in primary osteoblasts, BrdU incorporation, ChIP, double-transgenic (Sp7/Runx2) analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transgenic mouse with defined phenotype, ChIP, and loss-of-function in primary osteoblasts; multiple orthogonal approaches\",\n      \"pmids\": [\"22396760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In odontoblasts, BMP-2 activates Dspp gene transcription via a Dlx3/Osx signaling pathway; Osx is a downstream target of Dlx3, and both Dlx3 and Osx activate the Dspp promoter. Protein-protein interaction between Dlx3 and Osx in odontoblasts was detected by Co-IP; two Dlx3 and one Osx binding sites on the Dspp promoter were confirmed by EMSA and ChIP.\",\n      \"method\": \"Co-IP, EMSA, ChIP, promoter-reporter/mutagenesis assays, luciferase assays, in vitro and in vivo BMP-2 treatment\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — Co-IP, EMSA, ChIP, mutagenesis all in one study; single lab\",\n      \"pmids\": [\"28883412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TIEG1/KLF10 directly binds to and activates the Osterix promoter (confirmed by ChIP); TIEG1 is required for TGFβ- and BMP2-induced Osterix expression in osteoblasts. Loss of TIEG1 decreases Osterix mRNA, and restoration of TIEG1 in knockout osteoblasts rescues Osterix expression.\",\n      \"method\": \"ChIP, transfection reporter assays, siRNA knockdown, TIEG1 KO osteoblasts, domain mapping (zinc finger domain required)\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with reporter assay and genetic rescue; single lab, multiple methods\",\n      \"pmids\": [\"26801561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Conditional deletion of Osterix (Osx) in chondrocytes (Col2-Cre-ERT2) impairs secondary ossification in the tibial epiphysis, reducing trabecular bone mass, trabecular number, and expression of MMP13, COL10, ALP, and BSP; Osx overexpression in ATDC5 chondrocytes increases Col10, Mmp13, Alp, and Bsp expression, supporting a role for chondrocyte Osx in regulating genes involved in hypertrophy and osteoblast transdifferentiation.\",\n      \"method\": \"Conditional knockout mice (Osx fl/fl; Col2-Cre-ERT2), tamoxifen induction, µCT, histology, IHC, overexpression in ATDC5 cells\",\n      \"journal\": \"Bone research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined skeletal phenotype, IHC, and gain-of-function in cell line; single lab, multiple approaches\",\n      \"pmids\": [\"31646014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Sp7 directly regulates dlx2b and bglap expression in zebrafish through Sp7-binding sites on their promoters (confirmed by cell transfection reporter assays); loss of sp7 by CRISPR/Cas9 knockout reduces dlx2b and bglap expression and causes defects in bone mineralization and tooth development.\",\n      \"method\": \"CRISPR/Cas9 knockout in zebrafish, qRT-PCR, cell transfection promoter assays\",\n      \"journal\": \"Journal of biosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined phenotype and promoter assays; single lab\",\n      \"pmids\": [\"31894108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Melatonin inhibits ubiquitin-proteasome-mediated degradation of Osterix, thereby stabilizing its expression and increasing Osterix transcriptional activity on the osteogenic promoter. Melatonin-induced Osterix phosphorylation and transcriptional activity are blocked by PKA inhibitor H89 and PKC inhibitor Go6976.\",\n      \"method\": \"Proteasome inhibitor treatment, ubiquitination assays, PKA/PKC inhibitors, reporter assays, osteogenic differentiation assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological pathway dissection with functional readouts; single lab, mechanisms inferred through inhibitors rather than direct protein modification mapping\",\n      \"pmids\": [\"28720849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The human SP7 gene encodes a 431 amino acid C2H2 zinc finger transcription factor of the SP family with three consecutive C2H2 zinc finger repeats; two alternatively spliced isoforms exist. SP7 maps to chromosome 12q13.13. SP7 mRNA is restricted to osteoblast-derived cell lines in vitro and is expressed specifically in osteoblasts in vivo (confirmed by in situ hybridization on human embryonic tissues).\",\n      \"method\": \"cDNA cloning, Northern blot, in situ hybridization, FISH (chromosomal mapping), sequence analysis\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct cloning, localization by ISH, and chromosomal mapping; single lab, multiple methods\",\n      \"pmids\": [\"15474293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Osteoblast-specific deletion of Sp7 (using 2.3-kb Col1a1-EGFP-Cre) reveals that Sp7 inhibits proliferation of immature osteoblasts, induces osteoblast maturation and Col1a1 expression, and is required for osteocyte process formation; Sp7 overexpression directly induces Col1a1 expression. Loss of Sp7 in osteoblasts causes reduced osteocyte canaliculi, increased TUNEL-positive lacunae, increased osteoclasts, and cortical porosity.\",\n      \"method\": \"Conditional knockout mice (Sp7 fl/fl; 2.3kb-Col1a1-EGFP-Cre), hypomorphic Sp7 mice, micro-CT, histomorphometry, BrdU incorporation, RT-PCR, primary osteoblast cultures, Sp7 overexpression\",\n      \"journal\": \"Journal of orthopaedic translation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent genetic mouse models with comprehensive skeletal analyses and gain-of-function validation; multiple orthogonal methods\",\n      \"pmids\": [\"39027344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SIRT7 forms a complex with RBM6 that downregulates H3K18 acetylation at the OSX promoter, inhibiting OSX isoform 1 and 2 expression and osteogenic differentiation of MSCs. lncRNA PLXDC2-OT associates with the SIRT7/RBM6 complex, diminishing its binding and deacetylation activity at the OSX promoter and thereby promoting osteogenesis.\",\n      \"method\": \"Co-IP (SIRT7-RBM6 interaction), ChIP (H3K18Ac at OSX promoter), siRNA knockdown, lncRNA-protein interaction assay, osteogenic differentiation assays in vitro and in vivo\",\n      \"journal\": \"Stem cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ChIP, and functional rescue; single lab, multiple methods\",\n      \"pmids\": [\"33684230\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SP7/Osterix is an osteoblast-specific C2H2 zinc finger transcription factor that acts downstream of BMP2/Runx2/Dlx5 signaling to drive osteoblast and osteocyte differentiation; it binds AT-rich osteoblast enhancers primarily as a co-factor with Dlx proteins (rather than canonical GC-boxes), physically interacts and cooperates with Runx2 to synergistically activate target genes (Col1a1, Ibsp, VEGF, MMP13, Satb2, SOST, osteocalcin, collagens V, DKK1, Osteocrin), and its transcriptional activity is modulated by multiple post-translational modifications—phosphorylation by p38 MAPK (Ser-73/77) and ERK/Akt, acetylation by CBP at K307/K312 (removed by HDAC4), deacylation at K368 by SIRT7—as well as by ubiquitin-proteasome-mediated degradation and epigenetic control of its own promoter via DNA methylation/demethylation (Tet1/2) and histone-modifying complexes including the repressor NO66.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SP7/Osterix is an osteoblast-specific C2H2 zinc finger transcription factor of the SP family whose expression is restricted to osteoblast lineage cells and required for osteoblast and osteocyte differentiation [#40, #41]. It is induced downstream of BMP-2 through both Runx2-dependent and Runx2-independent routes: Runx2 directly transactivates the Osx promoter [#1], while a parallel Dlx5-mediated arm—itself amplified by p38 MAPK phosphorylation of Dlx5—drives Osx independently of Runx2 [#0, #2], with Smad1/Smad4/Msx2 providing an additional Runx2-independent input [#3]. Unlike canonical SP proteins, the SP7 zinc finger has reduced GC-box affinity and instead is recruited to AT-rich osteoblast enhancers via interaction with Dlx5, defining a non-canonical co-factor mode of DNA engagement [#6]; the disease relevance of this specificity is shown by a de novo neomorphic SP7 p.S309W variant that switches binding from AT-rich to GC-consensus sites and produces an aberrant osteogenic program and a distinct skeletal phenotype in knock-in mice [#21]. SP7 also physically interacts with Runx2 and synergistically activates phenotype-restricted target genes, a cooperation requiring adjacent SP1/Runx2 sites and MAPK-dependent phosphorylation of both factors [#5, #18]. Through these mechanisms SP7 directly activates a broad osteogenic transcriptional program—including Satb2, VEGF, MMP13, SOST, fibromodulin, bone sialoprotein, type V and type I collagens, and Osteocrin—and in osteocytes drives dendrite/process formation, with Osteocrin acting as a direct target that rescues dendrite defects [#9, #10, #11, #8, #41]. SP7 transcriptional output is tuned by extensive post-translational control: stimulatory phosphorylation by p38 MAPK (Ser-73/77, enhancing p300/Brg1 recruitment), ERK, and Akt [#4, #12, #13], acetylation by CBP at K307/K312 reversed by HDAC4 [#15], SIRT7-mediated deacylation at K368 [#7], and ubiquitin-proteasome-mediated degradation at K58/K230 [#14]; it is repressed by physical interaction with p53, which blocks both its DNA binding and its Dlx5 co-factor activity [#17]. SP7 expression is itself governed by epigenetic switching of its promoter—silencing via DNMT/HDAC/Setdb1/Ezh repressor complexes and activation via Tet1/Tet2 demethylation and SWI/SNF remodeling—and by positive autoregulation through an SP7-selective promoter element [#20, #33, #34].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established that BMP-2 induction of Osterix proceeds through Dlx5 independently of Runx2, revealing a branched upstream signaling logic for osteoblast commitment.\",\n      \"evidence\": \"Dlx5 antisense knockdown, Runx2-null cells, and Runx2 overexpression with BMP-2 treatment and RT-PCR\",\n      \"pmids\": [\"12963046\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not map the Dlx5 element on the Osx promoter\", \"Did not exclude additional parallel inputs\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed Runx2 directly binds and transactivates the Osx promoter, defining a Runx2-dependent arm of Osx induction alongside the Dlx5 route.\",\n      \"evidence\": \"Luciferase promoter-reporter assays, deletion/mutation analysis, EMSA, and 5' RACE\",\n      \"pmids\": [\"16574347\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vitro promoter assays only\", \"Relative contribution of Runx2 vs Dlx5 arms in vivo not quantified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified the Dlx5 homeodomain element on the Osx promoter and showed p38 phosphorylation of Dlx5 amplifies its transactivation, connecting BMP signaling to Osx induction mechanistically.\",\n      \"evidence\": \"Promoter-reporter assays, ChIP, kinase assays, and Dlx5 mutagenesis\",\n      \"pmids\": [\"18056716\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Focused on Dlx5 regulation rather than Osx protein function\", \"Did not address Osx auto-feedback\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined a Smad1/Smad4/Msx2-mediated Runx2-independent route for BMP2-driven Osx, expanding the upstream network beyond Dlx5.\",\n      \"evidence\": \"Smad/Msx2 overexpression, Msx2 siRNA in Runx2-null cells, RT-PCR, and microarray\",\n      \"pmids\": [\"18703512\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct Smad/Msx2 binding sites on Osx promoter not mapped\", \"Crosstalk with Dlx5 arm unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated that p38 phosphorylation of Osterix at Ser-73/77 promotes coactivator recruitment, establishing PTM-controlled assembly of the transcriptional machinery at target promoters.\",\n      \"evidence\": \"Kinase assays, mutagenesis, ChIP, Co-IP with p300/Brg1, and reporter assays\",\n      \"pmids\": [\"20682789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"GC-box binding model later refined by non-canonical AT-rich mode\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established that Osx and Runx2 physically interact and cooperatively activate osteogenic genes in a MAPK-phosphorylation-dependent manner, unifying the two upstream factors as a transcriptional complex.\",\n      \"evidence\": \"Co-IP, domain mapping, promoter-reporter assays, MAPK inhibition, and ChIP across two studies\",\n      \"pmids\": [\"25122769\", \"25158187\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structure of the Osx-Runx2 complex unknown\", \"Genome-wide co-occupancy not mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Resolved the central paradox of SP7's atypical DNA binding: its zinc finger has reduced GC-box affinity and engages AT-rich osteoblast enhancers via Dlx5, redefining SP7 as a Dlx-recruited co-factor.\",\n      \"evidence\": \"ChIP-seq, transgenic enhancer assays, domain mapping, and sequence comparison\",\n      \"pmids\": [\"27134141\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the Dlx5-zinc finger interface not solved\", \"Direct vs indirect enhancer occupancy distinction incomplete\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified SIRT7-mediated deacylation at K368 as a post-translational activator of Osx, linking a sirtuin to bone formation in vivo.\",\n      \"evidence\": \"Co-IP, in vitro deacylation assay, K368 mutagenesis, and germline/osteoblast-specific Sirt7 knockout mice\",\n      \"pmids\": [\"30026585\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Acyl group identity at K368 not fully defined\", \"Interplay with other Osx PTMs not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established SP7's role in osteocyte dendrite formation and identified Osteocrin as a direct, rescuing target, extending SP7 function beyond osteoblast commitment into osteocyte maturation.\",\n      \"evidence\": \"Conditional knockout mice, ChIP-seq, single-cell RNA-seq, Osteocrin rescue, and human variant analysis\",\n      \"pmids\": [\"34725346\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of dendrite-relevant SP7 targets not enumerated\", \"Mechanism by which Osteocrin shapes dendrites unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A neomorphic SP7 p.S309W variant that converts DNA-binding specificity from AT-rich to GC-consensus directly demonstrated that SP7's atypical specificity is functionally essential and disease-relevant.\",\n      \"evidence\": \"Biochemical DNA-binding analysis, knock-in mouse model, and expression profiling\",\n      \"pmids\": [\"35121733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism of the specificity switch not solved\", \"Spectrum of clinical SP7 variants not catalogued here\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Comprehensive osteoblast-specific knockout defined SP7's dual role in suppressing immature osteoblast proliferation while driving maturation, Col1a1 expression, and osteocyte process formation.\",\n      \"evidence\": \"Two conditional/hypomorphic mouse models, micro-CT, histomorphometry, BrdU, and gain-of-function in primary osteoblasts\",\n      \"pmids\": [\"39027344\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct targets mediating proliferation arrest not identified\", \"Mechanism of increased osteoclast/cortical porosity downstream unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the many post-translational modifications, p53 repression, and epigenetic promoter switches are integrated dynamically to set SP7 activity thresholds during osteoblast-to-osteocyte transition remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of the SP7-Dlx5-Runx2 enhancer complex\", \"Hierarchy and crosstalk among PTMs not established\", \"Quantitative model linking SP7 dosage to lineage stage lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [40, 6, 9, 10, 11, 5, 34]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [6, 21, 9, 11, 22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [40, 15, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [9, 10, 11, 6, 5]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 8, 37, 41]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [19, 20, 42]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"DLX5\", \"RUNX2\", \"SIRT7\", \"TP53\", \"CBP\", \"NO66\", \"DLX3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}